Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma cell leukemia: a rare condition.

Víctor Hugo Jiménez-Zepeda1, Virginia Jeanet Domínguez

  • 1Department of Hematology/Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Colonia sección XVI, Tlalpan, CP14000, Mexico. vhugo8762@hotmail.com

Annals of Hematology
|January 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis.

Current oncology (Toronto, Ont.)·2025
Same author

High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.

Clinical lymphoma & myeloma·2009
Same author

Familial multiple myeloma: first case reported in a Mexican family.

Annals of hematology·2007
Same author

Acquired activated protein C resistance and thrombosis in multiple myeloma patients.

Thrombosis journal·2006
Same author

Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?

European journal of haematology·2006

Plasma cell leukemia (PCL), a rare blood cancer, often presents aggressively with a poor prognosis. This study analyzed ten PCL cases, finding primary PCL more common and a short mean survival of 5.9 months.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Plasma cell leukemia (PCL) is a rare, aggressive lymphoproliferative disorder.
  • It is characterized by malignant plasma cell proliferation in blood and bone marrow.
  • PCL has primary (de novo) and secondary (transformation from multiple myeloma) forms.

Purpose of the Study:

  • To report clinical characteristics, treatment response, and outcomes of ten PCL cases.
  • To describe specific complications like activated protein C resistance and venous thrombosis.
  • To compare findings with existing literature on PCL prognosis.

Main Methods:

  • Retrospective case series analysis of ten PCL patients.
  • Data collection on demographics, clinical presentation, diagnosis (Kyle's criteria), and treatment.

Related Experiment Videos

  • Analysis of survival data and incidence of complications.

    • Main Results:

    • Median age 58 years, 70% female; 80% primary PCL (PPCL), 20% secondary PCL (SPCL).
    • Reported one case of secondary PCL with acquired activated protein C resistance.
    • Observed 20% incidence of venous thrombosis in PPCL patients; mean survival 5.9 months.

    Conclusions:

    • PCL remains a disease with a poor prognosis and short survival, consistent with literature.
    • The study highlights the occurrence of specific complications like APC resistance and venous thrombosis in PCL.
    • Further research into PCL pathogenesis and treatment strategies is warranted.